Dr Lal PathLabs filed its Business Responsibility and Sustainability Report for the financial year 2025-26 with the National Stock Exchange of India and BSE Limited. The disclosure, submitted by Vinay Gujral, Company Secretary & Compliance Officer, outlines the company's performance against the National Guidelines on Responsible Business Conduct (NGRBC).

The report details environmental metrics such as total energy consumption of 79,829 GJ and water withdrawal of 1,36,426 kilolitres, alongside social data including a workforce of 5,611 and CSR expenditure of ₹10.54 million.

Environmental Performance

The company reported a total energy consumption of 79,829 GJ for FY 2025-26, comprising 12,000 GJ from renewable sources and 67,829 GJ from non-renewable sources. The energy intensity stood at 0.0000000012 GJ per rupee of revenue from operations.

Water withdrawal totalled 1,36,426 kilolitres, entirely sourced from municipal corporations, with total water discharge matching the withdrawal volume. The water intensity was reported at 0.00000000014 kilolitres per rupee of revenue from operations.

Regarding waste management, the entity generated 829.44 metric tonnes of total waste. This included 8.08 metric tonnes of non-hazardous waste and 821.36 metric tonnes of other waste. The company recovered 1.61 metric tonnes through recycling and re-using operations, while 827.84 metric tonnes were disposed of via incineration and other methods.

Social and Governance Metrics

As of March 31, 2026, the company employed 1,981 individuals and engaged 3,630 workers. The workforce included 29 differently abled workers and 2 differently abled employees. The report noted that 98.69% of employees and 99.12% of workers received training on human rights issues.

The company reported no instances of fines, penalties, or imprisonment related to regulatory non-compliance during the year. It also recorded zero data breaches and no product recalls due to safety issues.

Corporate Social Responsibility

Corporate Social Responsibility (CSR) activities were applicable for the year. The company spent a total of ₹10.54 million on CSR projects undertaken in designated aspirational districts. The report indicated that the company does not have a preferential procurement policy for marginalized or vulnerable groups.

The filing confirms that the Board has approved policies covering all nine principles of the NGRBC. An independent assurance statement was provided by J Sundharesan & Associates, verifying the BRSR core indicators.

Dr Lal PathLabs Limited has filed its Annual Report for the Financial Year 2025-26 with the National Stock Exchange of India Limited and BSE Limited, pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report was submitted on July 1, 2026, and signed by Vinay Gujral, Company Secretary & Compliance Officer.

Financial Performance: Consolidated and Standalone

The company delivered consistent growth across both consolidated and standalone metrics in FY 2025-26. The following table summarises the key financial results:

Consolidated revenue from operations reached ₹27,629 million in FY 2026, up 12.2% from ₹24,614 million in FY 2025. Reported EBITDA for FY 2026 stood at ₹7,524 million; excluding the one-time charge of ₹301 million related to the implementation of the new Labour Code, EBITDA stood at ₹7,825 million, reflecting growth of 12.5% over FY 2025. EBITDA margins remained steady at 28.3%. On a normalised basis, PAT increased by 17.9% to ₹5,323 million during the year. The company reported cash and cash equivalents of ₹15,262 million in FY 2026, compared to ₹12,295 million in FY 2025, and remains debt-free.

Shareholder Returns: Bonus Issue and Dividend

The Board approved a 1:1 bonus issue, allotting 8,37,75,510 fully paid-up bonus equity shares on December 22, 2025, by capitalising ₹837.75 million from the Securities Premium account. As a result, the paid-up share capital increased from ₹83,59,17,350 to ₹1,67,55,50,200. A total dividend of 280% on equity share capital was declared for FY 2026, comprising the following tranches:

Operational Highlights and Network Expansion

During FY 2025-26, the company added 14 laboratories and over 1,100 collection centres, strengthening its cluster-led expansion strategy. Key operational metrics are summarised below:

Tier 3+ markets contributed 39% of revenue in FY 2026. Over the last four years, the company added 2,625 PSCs and 2,997 pick-up points across India.

Strategic and Innovation Milestones

FY 2025-26 marked several strategic milestones for the company:

• Launch of Sovaaka: An AI-powered precision health screening and preventive wellness platform, inaugurated with the participation of the Chief Minister of Haryana.
• Medllumina: The company's first international medical conference on diagnostics and precision medicine, bringing together over 500 clinicians, researchers and global experts.
• First-in-India Diagnostic Tests: 13 new first-in-India diagnostic tests were introduced during FY 2026, including Amyloid Typing by Laser Capture Microdissection and Mass Spectrometry — the first such offering in South Asia.
• AI in Oncology: The company became the first laboratory in India to integrate a deep learning-based AI module for detecting lymph node metastasis, including micrometastasis.
• R&D: Over 35 internal research projects were initiated, and more than 40 scientific papers were published in national and international journals. R&D expenditure stood at ₹48.55 million.
• Credit Rating Upgrade: The company's credit rating was upgraded from CARE AA; Stable to CARE AA+; Stable.

CSR and Sustainability

The company's CSR arm, Lal PathLabs Foundation, spent ₹102.16 million against a CSR obligation of ₹102.02 million in FY 2025-26. The flagship Phlebotomist Training Program certified 3,100+ candidates and placed 2,500+ candidates during the year, with 62% of certified candidates being women. Since inception in 2018, over 13,000 phlebotomists have been trained and over 10,700+ placed. The Foundation reached over 1,00,000 direct beneficiaries across 42 locations through its public health programmes. On the environmental front, the company's 3.22 MW solar capacity generated 34.60 lakh kWh of green energy in FY 2025-26, resulting in CO2 emissions savings of 2,515 metric tonnes, while its RO wastewater recycling programme recovered approximately 9,125.3 KL of water.

Corporate Governance and Board

The Board comprised nine directors as on March 31, 2026, including two Executive Directors, two Non-Executive Directors and five Non-Executive Independent Directors. The Board met four times during FY 2025-26. Key managerial personnel as on March 31, 2026 included (Hony) Brig Dr Arvind Lal as Executive Chairman, Dr Vandana Lal as Whole-Time Director, Shankha Banerjee as CEO, Ved Prakash Goel as Group CFO & CEO – International Business, and Vinay Gujral as Company Secretary & Compliance Officer. The 32nd Annual General Meeting is scheduled for Saturday, July 25, 2026.